CERAMENT[®] G with Gentamicin

VALUE PROPOSITION

CERAMENT® G is the first and only injectable antibiotic eluting bone graft indicated for use in bone infection.

The Burden of Bone Infection

Despite medical advancements and use of systemic antibiotics, bone infection remains a challenge. Moreover, bone infections are associated with an increased risk of amputation.

- 1 in 5 infections recur¹
- 2+ surgical interventions typically required²
- 20 30% long term recurrence rate³
- \$51K more treatment costs for infected patients⁴

A New Patient Friendly and Fiscally Prudent Pathway

CERAMENT[®] G addresses two clinical needs; bone remodeling and protected bone healing, leading to significant cost savings and improved clinical outcomes.



Enables a Single-Stage Surgical Approach that is Clinically Proven



CERAMENT® G Helps Reduce Readmissions, Length of Stay and Costs

Oxford Health Economic Data Publication

66% reduction in readmissions¹⁰

5X lower risk of death¹⁰

17 fewer bed days¹⁰

\$10,907 direct cost savings per patient from reduced length of stay¹⁰

* Compared to UKs top 10 osteomyelitis facilities

US Based Health Economic Model¹¹

50 - 60% reduction in surgeries/reinfections¹¹

- Improve patient satisfaction
- Limit risk of reimbursement penalties
- Decrease cost of care



Reimbursement

- \$4,918 maximum reimbursement
- ICD-10-PCS Code: XW0V0P7

REIMBURSEMENT HOTLINE:

TO ORDER CERAMENT® G:

New technology add on payment (NTAP)

- Offsets product cost, reducing financial impact
- Unique ICD-10 Procedure Code
- Supports access to new technology

Email: usreimbursement@bonesupport.com Phone: 1-866-903-2663

Email: us.sales@bonesupport.com Phone: 1-877-719-6719

- Conterno, L.O., Turchi, M.D. Antibiotics for treating chronic osteomyelitis in adults. Cochrane Database Syst Rev. 2013;2013(9). 1.
- Bezstarosti et al. Insights into treatment and outcome of fracture-related infection: a systematic literature review. Arch Orthop Trauma Surg 139, 61–72 (2019). Pande K. Optimal management of chronic osteomyelitis: current perspectives. Orthop Res Rev. 2015;7:71-81. 2 3.
- Thakore et al. Sethi MK. Surgical site infection in orthopedic trauma: A case-control study evaluating risk factors and cost. J Clin Orthop Trauma. 2015 Dec;6(4):220-6. doi: 10.1016/j.jcot.2015.04.004. Epub 2015 Jun 18. PMID: 26566333; PMCID: PMC4600831. 4
- Ferguson et al. 'Radiographic and Histological Analysis of a Synthetic Bone Graft Substitute Eluting Gentamicin in the Treatment of Chronic Osteomyelitis'. J. Bone Joint Infect. 2019; 4(2): 76-84. 5.
- 6
- S038/2023.BONESUPPORT data on file. Aureus MBIC level: Mottola et al. 'Susceptibility patterns of Staphylococcus aureus biofilms in diabetic foot infections'. BMC Microbiology 2016; 16:119. https:// 7.
- https://en.wikipedia.org/wiki/Minimum_inhibitory_concentration [accessed 24th September 2019]. 8
- McNally et al. Single-stage treatment of chronic osteomyelitis with a new absorbable, gentamicin-loaded, calcium sulphate/ hydroxyapatite biocomposite? Bone 9. Joint J. 2016 Sep; 98-B(9):1289-96.
- 10 Ferguson et al. A retrospective cohort study comparing clinical outcomes and healthcare resource utilisation in patients undergoing surgery for osteomyelitis in England: a case for reorganising orthopaedic infection services. Journal of bone and joint infection vol. 6,5 151-163. 28 Apr. 2021.
- M.J. Carter, PhD1, P.S. Čalara, MSc2, M. Diefenbeck, MD PhD3, P.E. Matuszewski, MD4, A. Agarwal, MD5, D.C. Allison, MD, FACS6: Cost-Effectiveness of Single 11. Stage Surgery of Osteomyelitis. SOMOS Conference Presentation Session 7A: Research - Trauma, Arizona, 2022. SOMOS 64th Annual Meeting (xcdsystem.com)



BONESUPPORT, INC., 60 William St, Suite 330 Wellesley, MA 02481

T: 1.877.719.6718 E: us.sales@bonesupport.com W: bonesupport.com



PR-01325 en US 1-2023